scholarly article | Q13442814 |
P50 | author | Suresh Senan | Q37830477 |
P2093 | author name string | Adrianus J de Langen | |
Max Dahele | |||
Ben Slotman | |||
Wilko Verbakel | |||
Sayed Hashemi | |||
Hilâl Tekatli | |||
Esther Nossent | |||
Femke Spoelstra | |||
Eva Bongers | |||
Niels Haasbeek | |||
Patricia De Haan | |||
P433 | issue | 7 | |
P921 | main subject | adaptive radiation therapy | Q180507 |
P304 | page(s) | 1081-1089 | |
P577 | publication date | 2016-03-21 | |
P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
P1476 | title | Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer. | |
P478 | volume | 11 |
Q28079625 | A critical review of recent developments in radiotherapy for non-small cell lung cancer |
Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
Q92846083 | Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors |
Q99240991 | Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review |
Q89869712 | Contrast enhanced oesophageal avoidance for stereotactic body radiotherapy: Barium vs. Gastrografin |
Q99582784 | Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis |
Q61443804 | Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy |
Q61804647 | Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation |
Q42668963 | Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation |
Q91734109 | Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report |
Q92891968 | Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer |
Q92675935 | Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer |
Q89924278 | Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors |
Q48202266 | Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). |
Q94672120 | Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic |
Q48282380 | Rethink radiotherapy - BIGART 2017. |
Q92973685 | Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer |
Q39135612 | SBRT for centrally localized NSCLC - What is too central? |
Q53822924 | Standard of care in high-dose radiotherapy for localized non-small cell lung cancer. |
Q64956876 | Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial. |
Q55224635 | Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk? |
Q89507738 | Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer |
Q57172947 | Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances |
Q55282076 | Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives. |
Q57177641 | Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions |
Q61804651 | Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer |
Q90017826 | Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes |
Q90175125 | The evolving role of radiotherapy in non-small cell lung cancer |
Q61804650 | The evolving toxicity profile of SBRT for lung cancer |
Q55441971 | [Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer]. |
Search more.